Seres Therapeutics Inc MCRB Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.98 down $0.11, 5.26% at close Nov 6
Last close · Previous close $2.09
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$1.98down $0.92, 31.72%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.09Nov 5
- Volume82.28KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume71.03KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.68 to $29.98; now $1.98
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
MCRB trailed the S&P 500 in all 7 periods.
| Period | MCRB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MCRB: down 31.7% S&P 500: down 5.6% | MCRB trailed the S&P 500 by 26.1 percentage points Trailed |
| 3M | MCRB: down 58.9% S&P 500: down 4.1% | MCRB trailed the S&P 500 by 54.8 percentage points Trailed |
| YTD | MCRB: down 86.7% S&P 500: up 8.7% | MCRB trailed the S&P 500 by 95.4 percentage points Trailed |
| 1Y | MCRB: down 85.7% S&P 500: up 10.9% | MCRB trailed the S&P 500 by 96.6 percentage points Trailed |
| Long term | ||
| 3Y | MCRB: down 91.3% S&P 500: up 75.0% −55.7% vs +20.5% a year | MCRB trailed the S&P 500 by 166.3 percentage points Trailed |
| 5Y | MCRB: down 98.6% S&P 500: up 67.8% −57.3% vs +10.9% a year | MCRB trailed the S&P 500 by 166.4 percentage points Trailed |
| 10Y | MCRB: down 99.0% S&P 500: up 313.1% −37.2% vs +15.2% a year | MCRB trailed the S&P 500 by 412.1 percentage points Trailed |
$10,000 invested in MCRB 10 years ago (Nov 4, 2016) would be worth about $95 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
MCRB trailed the S&P 500 in all 7 periods.
| Period | MCRB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MCRB: down 31.7% S&P 500: down 5.6% | MCRB trailed the S&P 500 by 26.1 percentage points Trailed |
| 3M | MCRB: down 58.9% S&P 500: down 4.3% | MCRB trailed the S&P 500 by 54.6 percentage points Trailed |
| YTD | MCRB: down 86.7% S&P 500: up 7.8% | MCRB trailed the S&P 500 by 94.5 percentage points Trailed |
| 1Y | MCRB: down 85.7% S&P 500: up 9.7% | MCRB trailed the S&P 500 by 95.4 percentage points Trailed |
| Long term | ||
| 3Y | MCRB: down 91.3% S&P 500: up 68.8% −55.7% vs +19.1% a year | MCRB trailed the S&P 500 by 160.1 percentage points Trailed |
| 5Y | MCRB: down 98.6% S&P 500: up 56.9% −57.3% vs +9.4% a year | MCRB trailed the S&P 500 by 155.5 percentage points Trailed |
| 10Y | MCRB: down 99.0% S&P 500: up 252.6% −37.2% vs +13.4% a year | MCRB trailed the S&P 500 by 351.6 percentage points Trailed |
$10,000 invested in MCRB 10 years ago (Nov 4, 2016) would be worth about $95 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$1,028.00
Closing high on . Now 99.8% below that record.
Split-adjusted daily closes since Jun 26, 2015.
Stock splits
1
1-for-20 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $1.88M
- Net income
- −$22.46M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | $88.78M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$15.64M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | $32.68M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$19.86M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $351.00K | $8.20M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $438.00K | −$15.34M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $358.00K | −$19.91M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $736.00K | $4.58M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $144.93M | −$65.58M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$250.16M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$113.72M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | $136.00K | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $789.00K | $5.70M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating −4,462.8%
- Net −1,192.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$51.07MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$51.26MLast 12 months
- Capital spending$187.00KLast 12 months
- −2,712.2%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $14.86MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $17.84MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$56.64MAs of Jun 30, 2026
- Net debt$38.81MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 2.11As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 1.64As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −60.3%Last 12 months
Over the last 12 months, Seres Therapeutics lost money: its net loss was 60.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −17.9%Last 12 months
Over the last 12 months, Seres Therapeutics’s net loss was 17.9% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Seres Therapeutics Inc
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received both Breakthrough Therapy and Fast Track designation, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
MCRB news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
MCRB stock FAQ
What is MCRB stock’s price today?
Seres Therapeutics (MCRB) traded at $1.98 at the close on , down $0.11 (5.26%) from the previous close of $2.09. Over the past 52 weeks it has traded between $1.68 and $29.98.
If you invested $1,000 in MCRB 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in MCRB on would be worth about $10 at the close on , a total return of −99.0%. The same $1,000 would be worth $14 if invested five years ago and $143 if invested one year ago. Past performance doesn’t predict future returns.
How much revenue does Seres Therapeutics make?
Seres Therapeutics reported $1.9 million of revenue over the four quarters to . In its latest quarter (Q2 FY26, ended ) revenue was $736.0 thousand.
Is Seres Therapeutics profitable?
Not over the four quarters to . Seres Therapeutics reported a net loss of $22.5 million across those four quarters on $1.9 million of revenue.
Does MCRB pay a dividend?
Seres Therapeutics hasn’t paid a dividend in the last twelve months.
What is MCRB’s 52-week high and low?
Over the past 52 weeks MCRB has traded as low as $1.68 and as high as $29.98. At $1.98 at the close on , it is 93.4% below that high and 18.2% above the low.
What is MCRB’s all-time high?
MCRB’s highest closing price was $1,028.00 on , adjusted for stock splits. At $1.98 at the close on , it is 99.8% below that record.
Has MCRB stock ever split?
Yes, once: 1-for-20 on .
How has MCRB stock performed?
Including dividends and measured to the close on , MCRB has returned −86.7% so far this year and −85.7% over the past year, and −98.6% over five years (−57.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Seres Therapeutics in?
Seres Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does MCRB trade on?
Seres Therapeutics trades on the Nasdaq under the ticker symbol MCRB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.